Astrana Health, Inc. (NASDAQ: ASTH) Stock Competitors & Peer Comparison
See ASTH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ASTH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ASTH | $39.19 | +0.08% | 2B | 37.88 | $1.04 | N/A |
| HCA | $406.97 | -1.16% | 88.1B | 14.05 | $28.96 | +0.73% |
| THC | $273.94 | +1.38% | 21.6B | 15.58 | $17.24 | N/A |
| FMS | $23.65 | +0.36% | 12.8B | 8.97 | $2.66 | +3.62% |
| EHC | $121.90 | -0.17% | 12.1B | 20.85 | $5.84 | +0.63% |
| BTSGU | $196.70 | +0.10% | 11.5B | 176.91 | $1.11 | N/A |
| DVA | $176.31 | -0.90% | 11.4B | 13.85 | $12.80 | N/A |
| ENSG | $180.38 | -1.16% | 10.6B | 26.45 | $6.90 | +0.14% |
| UHS | $173.80 | +0.41% | 10.4B | 7.65 | $22.54 | +0.46% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
HCA Healthcare, Inc. (NYSE: HCA)
ASTH vs HCA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, HCA has a market cap of 88.1B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while HCA trades at $406.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas HCA's P/E ratio is 14.05. In terms of profitability, ASTH's ROE is +0.05%, compared to HCA's ROE of -1.13%. Regarding short-term risk, ASTH is more volatile compared to HCA. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check HCA's competition here
Tenet Healthcare Corporation (NYSE: THC)
ASTH vs THC Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, THC has a market cap of 21.6B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while THC trades at $273.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas THC's P/E ratio is 15.58. In terms of profitability, ASTH's ROE is +0.05%, compared to THC's ROE of +0.51%. Regarding short-term risk, ASTH is less volatile compared to THC. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check THC's competition here
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)
ASTH vs FMS Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, FMS has a market cap of 12.8B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while FMS trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas FMS's P/E ratio is 8.97. In terms of profitability, ASTH's ROE is +0.05%, compared to FMS's ROE of +0.07%. Regarding short-term risk, ASTH is more volatile compared to FMS. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check FMS's competition here
Encompass Health Corporation (NYSE: EHC)
ASTH vs EHC Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, EHC has a market cap of 12.1B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while EHC trades at $121.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas EHC's P/E ratio is 20.85. In terms of profitability, ASTH's ROE is +0.05%, compared to EHC's ROE of +0.25%. Regarding short-term risk, ASTH is more volatile compared to EHC. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check EHC's competition here
BrightSpring Health Services, Inc. Tangible Equity Unit (NASDAQ: BTSGU)
ASTH vs BTSGU Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, BTSGU has a market cap of 11.5B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while BTSGU trades at $196.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas BTSGU's P/E ratio is 176.91. In terms of profitability, ASTH's ROE is +0.05%, compared to BTSGU's ROE of +0.15%. Regarding short-term risk, ASTH is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check BTSGU's competition here
DaVita Inc. (NYSE: DVA)
ASTH vs DVA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, DVA has a market cap of 11.4B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while DVA trades at $176.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas DVA's P/E ratio is 13.85. In terms of profitability, ASTH's ROE is +0.05%, compared to DVA's ROE of -1.24%. Regarding short-term risk, ASTH is more volatile compared to DVA. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check DVA's competition here
The Ensign Group, Inc. (NASDAQ: ENSG)
ASTH vs ENSG Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, ENSG has a market cap of 10.6B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while ENSG trades at $180.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas ENSG's P/E ratio is 26.45. In terms of profitability, ASTH's ROE is +0.05%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, ASTH is less volatile compared to ENSG. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check ENSG's competition here
Universal Health Services, Inc. (NYSE: UHS)
ASTH vs UHS Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, UHS has a market cap of 10.4B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while UHS trades at $173.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas UHS's P/E ratio is 7.65. In terms of profitability, ASTH's ROE is +0.05%, compared to UHS's ROE of +0.21%. Regarding short-term risk, ASTH is less volatile compared to UHS. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check UHS's competition here
Oak Street Health, Inc. (NYSE: OSH)
ASTH vs OSH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas OSH's P/E ratio is -17.65. In terms of profitability, ASTH's ROE is +0.05%, compared to OSH's ROE of +4.64%. Regarding short-term risk, ASTH is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check OSH's competition here
Chemed Corporation (NYSE: CHE)
ASTH vs CHE Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CHE has a market cap of 7B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CHE trades at $538.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CHE's P/E ratio is 24.84. In terms of profitability, ASTH's ROE is +0.05%, compared to CHE's ROE of +0.29%. Regarding short-term risk, ASTH is less volatile compared to CHE. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check CHE's competition here
PACS Group, Inc. (NYSE: PACS)
ASTH vs PACS Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, PACS has a market cap of 6.9B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while PACS trades at $44.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas PACS's P/E ratio is 23.17. In terms of profitability, ASTH's ROE is +0.05%, compared to PACS's ROE of +0.27%. Regarding short-term risk, ASTH is less volatile compared to PACS. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check PACS's competition here
LHC Group, Inc. (NASDAQ: LHCG)
ASTH vs LHCG Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas LHCG's P/E ratio is 82.83. In terms of profitability, ASTH's ROE is +0.05%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, ASTH is more volatile compared to LHCG. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check LHCG's competition here
LifeStance Health Group, Inc. (NASDAQ: LFST)
ASTH vs LFST Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, LFST has a market cap of 5B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while LFST trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas LFST's P/E ratio is 96.63. In terms of profitability, ASTH's ROE is +0.05%, compared to LFST's ROE of +0.03%. Regarding short-term risk, ASTH is more volatile compared to LFST. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check LFST's competition here
Concentra Group Holdings Parent, Inc. (NYSE: CON)
ASTH vs CON Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CON has a market cap of 4.4B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CON trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CON's P/E ratio is 24.13. In terms of profitability, ASTH's ROE is +0.05%, compared to CON's ROE of +0.47%. Regarding short-term risk, ASTH is less volatile compared to CON. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check CON's competition here
National HealthCare Corporation (AMEX: NHC)
ASTH vs NHC Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, NHC has a market cap of 3.7B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while NHC trades at $238.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas NHC's P/E ratio is 29.77. In terms of profitability, ASTH's ROE is +0.05%, compared to NHC's ROE of +0.13%. Regarding short-term risk, ASTH is less volatile compared to NHC. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check NHC's competition here
Option Care Health, Inc. (NASDAQ: OPCH)
ASTH vs OPCH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, OPCH has a market cap of 3.5B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while OPCH trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas OPCH's P/E ratio is 13.58. In terms of profitability, ASTH's ROE is +0.05%, compared to OPCH's ROE of +0.16%. Regarding short-term risk, ASTH is less volatile compared to OPCH. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check OPCH's competition here
Amedisys, Inc. (NASDAQ: AMED)
ASTH vs AMED Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AMED's P/E ratio is 39.30. In terms of profitability, ASTH's ROE is +0.05%, compared to AMED's ROE of +0.11%. Regarding short-term risk, ASTH is more volatile compared to AMED. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check AMED's competition here
Brookdale Senior Living Inc. (NYSE: BKD)
ASTH vs BKD Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while BKD trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas BKD's P/E ratio is -20.87. In terms of profitability, ASTH's ROE is +0.05%, compared to BKD's ROE of +4.06%. Regarding short-term risk, ASTH is less volatile compared to BKD. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check BKD's competition here
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH)
ASTH vs AVAH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AVAH has a market cap of 2.9B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AVAH trades at $13.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AVAH's P/E ratio is 19.35. In terms of profitability, ASTH's ROE is +0.05%, compared to AVAH's ROE of +1.50%. Regarding short-term risk, ASTH is less volatile compared to AVAH. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AVAH's competition here
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
ASTH vs ACHC Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, ACHC has a market cap of 2.5B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while ACHC trades at $27.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas ACHC's P/E ratio is 13.75. In terms of profitability, ASTH's ROE is +0.05%, compared to ACHC's ROE of -0.50%. Regarding short-term risk, ASTH is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check ACHC's competition here
Guardian Pharmacy Services, Inc. (NYSE: GRDN)
ASTH vs GRDN Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, GRDN has a market cap of 2.4B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while GRDN trades at $37.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas GRDN's P/E ratio is 33.32. In terms of profitability, ASTH's ROE is +0.05%, compared to GRDN's ROE of +0.31%. Regarding short-term risk, ASTH is more volatile compared to GRDN. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check GRDN's competition here
Addus HomeCare Corporation (NASDAQ: ADUS)
ASTH vs ADUS Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, ADUS has a market cap of 2.2B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while ADUS trades at $120.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas ADUS's P/E ratio is 17.97. In terms of profitability, ASTH's ROE is +0.05%, compared to ADUS's ROE of +0.10%. Regarding short-term risk, ASTH is less volatile compared to ADUS. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check ADUS's competition here
Pediatrix Medical Group, Inc. (NYSE: MD)
ASTH vs MD Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while MD trades at $26.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas MD's P/E ratio is 11.71. In terms of profitability, ASTH's ROE is +0.05%, compared to MD's ROE of +0.20%. Regarding short-term risk, ASTH is less volatile compared to MD. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check MD's competition here
Select Medical Holdings Corporation (NYSE: SEM)
ASTH vs SEM Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas SEM's P/E ratio is 15.43. In terms of profitability, ASTH's ROE is +0.05%, compared to SEM's ROE of +0.08%. Regarding short-term risk, ASTH is more volatile compared to SEM. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check SEM's competition here
Sonida Senior Living, Inc. (NYSE: SNDA)
ASTH vs SNDA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, SNDA has a market cap of 1.9B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while SNDA trades at $40.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas SNDA's P/E ratio is -7.54. In terms of profitability, ASTH's ROE is +0.05%, compared to SNDA's ROE of -0.26%. Regarding short-term risk, ASTH is less volatile compared to SNDA. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check SNDA's competition here
Apollo Medical Holdings, Inc. (NASDAQ: AMEH)
ASTH vs AMEH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AMEH's P/E ratio is 39.25. In terms of profitability, ASTH's ROE is +0.05%, compared to AMEH's ROE of +0.05%. Regarding short-term risk, ASTH is less volatile compared to AMEH. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AMEH's competition here
Surgery Partners, Inc. (NASDAQ: SGRY)
ASTH vs SGRY Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while SGRY trades at $13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas SGRY's P/E ratio is 34.87. In terms of profitability, ASTH's ROE is +0.05%, compared to SGRY's ROE of -0.05%. Regarding short-term risk, ASTH is less volatile compared to SGRY. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check SGRY's competition here
Healthcare Services Group, Inc. (NASDAQ: HCSG)
ASTH vs HCSG Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, HCSG has a market cap of 1.6B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while HCSG trades at $22.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas HCSG's P/E ratio is 18.34. In terms of profitability, ASTH's ROE is +0.05%, compared to HCSG's ROE of +0.24%. Regarding short-term risk, ASTH is more volatile compared to HCSG. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check HCSG's competition here
Agilon Health, Inc. (NYSE: AGL)
ASTH vs AGL Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AGL trades at $97.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AGL's P/E ratio is -10.48. In terms of profitability, ASTH's ROE is +0.05%, compared to AGL's ROE of -1.19%. Regarding short-term risk, ASTH is less volatile compared to AGL. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AGL's competition here
Ardent Health Inc. (NYSE: ARDT)
ASTH vs ARDT Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, ARDT has a market cap of 1.5B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while ARDT trades at $10.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas ARDT's P/E ratio is 8.59. In terms of profitability, ASTH's ROE is +0.05%, compared to ARDT's ROE of +0.05%. Regarding short-term risk, ASTH is less volatile compared to ARDT. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check ARDT's competition here
Innovage Holding Corp. (NASDAQ: INNV)
ASTH vs INNV Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, INNV has a market cap of 1.5B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while INNV trades at $10.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas INNV's P/E ratio is -121.56. In terms of profitability, ASTH's ROE is +0.05%, compared to INNV's ROE of -0.09%. Regarding short-term risk, ASTH is less volatile compared to INNV. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check INNV's competition here
AMN Healthcare Services, Inc. (NYSE: AMN)
ASTH vs AMN Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AMN has a market cap of 1.4B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AMN trades at $35.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AMN's P/E ratio is 11.74. In terms of profitability, ASTH's ROE is +0.05%, compared to AMN's ROE of +0.15%. Regarding short-term risk, ASTH is more volatile compared to AMN. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check AMN's competition here
The Pennant Group, Inc. (NASDAQ: PNTG)
ASTH vs PNTG Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, PNTG has a market cap of 1.4B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while PNTG trades at $39.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas PNTG's P/E ratio is 29.65. In terms of profitability, ASTH's ROE is +0.05%, compared to PNTG's ROE of +0.10%. Regarding short-term risk, ASTH is more volatile compared to PNTG. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check PNTG's competition here
Nutex Health, Inc. (NASDAQ: NUTX)
ASTH vs NUTX Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, NUTX has a market cap of 1.3B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while NUTX trades at $189.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas NUTX's P/E ratio is 14.50. In terms of profitability, ASTH's ROE is +0.05%, compared to NUTX's ROE of +0.52%. Regarding short-term risk, ASTH is less volatile compared to NUTX. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check NUTX's competition here
Brookdale Senior Living Inc. 7. (NYSE: BKDT)
ASTH vs BKDT Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas BKDT's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to BKDT's ROE of +4.06%. Regarding short-term risk, ASTH is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check BKDT's competition here
U.S. Physical Therapy, Inc. (NYSE: USPH)
ASTH vs USPH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while USPH trades at $79.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas USPH's P/E ratio is 31.15. In terms of profitability, ASTH's ROE is +0.05%, compared to USPH's ROE of -0.01%. Regarding short-term risk, ASTH is more volatile compared to USPH. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check USPH's competition here
Talkspace, Inc. (NASDAQ: TALK)
ASTH vs TALK Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, TALK has a market cap of 879.4M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while TALK trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas TALK's P/E ratio is 774.34. In terms of profitability, ASTH's ROE is +0.05%, compared to TALK's ROE of +0.00%. Regarding short-term risk, ASTH is more volatile compared to TALK. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check TALK's competition here
Fidelity Select Health Care Svcs Port (NASDAQ: FSHCX)
ASTH vs FSHCX Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, FSHCX has a market cap of 873.3M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while FSHCX trades at $114.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas FSHCX's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to FSHCX's ROE of N/A. Regarding short-term risk, ASTH is more volatile compared to FSHCX. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check FSHCX's competition here
GMR Solutions Inc. (NYSE: GMRS)
ASTH vs GMRS Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, GMRS has a market cap of 777.8M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while GMRS trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas GMRS's P/E ratio is 6.40. In terms of profitability, ASTH's ROE is +0.05%, compared to GMRS's ROE of +0.16%. Regarding short-term risk, ASTH is less volatile compared to GMRS. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check GMRS's competition here
Enhabit, Inc. (NYSE: EHAB)
ASTH vs EHAB Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas EHAB's P/E ratio is -197.14. In terms of profitability, ASTH's ROE is +0.05%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, ASTH is more volatile compared to EHAB. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check EHAB's competition here
Starling Oncology, Inc. (NASDAQ: STLN)
ASTH vs STLN Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, STLN has a market cap of 665.9M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while STLN trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas STLN's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to STLN's ROE of +2.10%. Regarding short-term risk, ASTH is less volatile compared to STLN. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check STLN's competition here
The Oncology Institute, Inc. (NASDAQ: TOI)
ASTH vs TOI Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, TOI has a market cap of 512.9M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while TOI trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas TOI's P/E ratio is -14.25. In terms of profitability, ASTH's ROE is +0.05%, compared to TOI's ROE of +2.10%. Regarding short-term risk, ASTH is less volatile compared to TOI. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check TOI's competition here
Strata Critical Medical, Inc. (NASDAQ: SRTA)
ASTH vs SRTA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, SRTA has a market cap of 509.6M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while SRTA trades at $5.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas SRTA's P/E ratio is -27.76. In terms of profitability, ASTH's ROE is +0.05%, compared to SRTA's ROE of +0.14%. Regarding short-term risk, ASTH is more volatile compared to SRTA. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check SRTA's competition here
Charming Medical Limited Class A Ordinary Shares (NASDAQ: MCTA)
ASTH vs MCTA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas MCTA's P/E ratio is 419.36. In terms of profitability, ASTH's ROE is +0.05%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, ASTH is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check MCTA's competition here
Community Health Systems, Inc. (NYSE: CYH)
ASTH vs CYH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CYH has a market cap of 413.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CYH trades at $2.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CYH's P/E ratio is 4.01. In terms of profitability, ASTH's ROE is +0.05%, compared to CYH's ROE of +0.21%. Regarding short-term risk, ASTH is more volatile compared to CYH. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check CYH's competition here
Auna S.A. (NYSE: AUNA)
ASTH vs AUNA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AUNA has a market cap of 404.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AUNA trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AUNA's P/E ratio is 4.92. In terms of profitability, ASTH's ROE is +0.05%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, ASTH is less volatile compared to AUNA. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AUNA's competition here
Viemed Healthcare, Inc. (NASDAQ: VMD)
ASTH vs VMD Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, VMD has a market cap of 340.5M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while VMD trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas VMD's P/E ratio is 24.83. In terms of profitability, ASTH's ROE is +0.05%, compared to VMD's ROE of +0.10%. Regarding short-term risk, ASTH is less volatile compared to VMD. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check VMD's competition here
Capital Senior Living Corporation (NYSE: CSU)
ASTH vs CSU Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CSU's P/E ratio is 0.67. In terms of profitability, ASTH's ROE is +0.05%, compared to CSU's ROE of -0.33%. Regarding short-term risk, ASTH is less volatile compared to CSU. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check CSU's competition here
AirSculpt Technologies, Inc. (NASDAQ: AIRS)
ASTH vs AIRS Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AIRS has a market cap of 198.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AIRS trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AIRS's P/E ratio is -93.67. In terms of profitability, ASTH's ROE is +0.05%, compared to AIRS's ROE of -0.13%. Regarding short-term risk, ASTH is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AIRS's competition here
The Joint Corp. (NASDAQ: JYNT)
ASTH vs JYNT Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, JYNT has a market cap of 117.6M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while JYNT trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas JYNT's P/E ratio is 82.50. In terms of profitability, ASTH's ROE is +0.05%, compared to JYNT's ROE of +0.22%. Regarding short-term risk, ASTH is more volatile compared to JYNT. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check JYNT's competition here
Park Dental Partners, Inc. Common Stock (NASDAQ: PARK)
ASTH vs PARK Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, PARK has a market cap of 99.1M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while PARK trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas PARK's P/E ratio is 29.65. In terms of profitability, ASTH's ROE is +0.05%, compared to PARK's ROE of -0.18%. Regarding short-term risk, ASTH is less volatile compared to PARK. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check PARK's competition here
Five Star Senior Living Inc. (NASDAQ: FVE)
ASTH vs FVE Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas FVE's P/E ratio is -5.64. In terms of profitability, ASTH's ROE is +0.05%, compared to FVE's ROE of -0.15%. Regarding short-term risk, ASTH is less volatile compared to FVE. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check FVE's competition here
Kindly MD, Inc. (NASDAQ: KDLYW)
ASTH vs KDLYW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas KDLYW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to KDLYW's ROE of -1.05%. Regarding short-term risk, ASTH is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check KDLYW's competition here
biote Corp. (NASDAQ: BTMD)
ASTH vs BTMD Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, BTMD has a market cap of 61.3M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while BTMD trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas BTMD's P/E ratio is 12.64. In terms of profitability, ASTH's ROE is +0.05%, compared to BTMD's ROE of -0.09%. Regarding short-term risk, ASTH is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check BTMD's competition here
AlerisLife Inc. (NASDAQ: ALR)
ASTH vs ALR Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas ALR's P/E ratio is -1.11. In terms of profitability, ASTH's ROE is +0.05%, compared to ALR's ROE of -0.15%. Regarding short-term risk, ASTH is more volatile compared to ALR. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check ALR's competition here
DocGo Inc. (NASDAQ: DCGO)
ASTH vs DCGO Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, DCGO has a market cap of 41.5M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while DCGO trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas DCGO's P/E ratio is -0.22. In terms of profitability, ASTH's ROE is +0.05%, compared to DCGO's ROE of -0.00%. Regarding short-term risk, ASTH is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check DCGO's competition here
P3 Health Partners Inc. (NASDAQ: PIII)
ASTH vs PIII Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, PIII has a market cap of 33.6M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while PIII trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas PIII's P/E ratio is -0.26. In terms of profitability, ASTH's ROE is +0.05%, compared to PIII's ROE of +1.61%. Regarding short-term risk, ASTH is less volatile compared to PIII. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check PIII's competition here
Cryo-Cell International, Inc. (AMEX: CCEL)
ASTH vs CCEL Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CCEL has a market cap of 33.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CCEL trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CCEL's P/E ratio is -13.73. In terms of profitability, ASTH's ROE is +0.05%, compared to CCEL's ROE of +0.14%. Regarding short-term risk, ASTH is less volatile compared to CCEL. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check CCEL's competition here
IMAC Holdings, Inc. (NASDAQ: IMAC)
ASTH vs IMAC Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas IMAC's P/E ratio is -2.27. In terms of profitability, ASTH's ROE is +0.05%, compared to IMAC's ROE of +0.00%. Regarding short-term risk, ASTH is less volatile compared to IMAC. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check IMAC's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
ASTH vs EUDA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, EUDA has a market cap of 26.4M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while EUDA trades at $13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas EUDA's P/E ratio is -26.64. In terms of profitability, ASTH's ROE is +0.05%, compared to EUDA's ROE of +1.20%. Regarding short-term risk, ASTH is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check EUDA's competition here
Cano Health, Inc. (NYSE: CANO-WT)
ASTH vs CANO-WT Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, ASTH is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check CANO-WT's competition here
Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH)
ASTH vs AIH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AIH's P/E ratio is -2.78. In terms of profitability, ASTH's ROE is +0.05%, compared to AIH's ROE of +1.16%. Regarding short-term risk, ASTH is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AIH's competition here
Cano Health, Inc. (NYSE: CANO)
ASTH vs CANO Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CANO's P/E ratio is -0.01. In terms of profitability, ASTH's ROE is +0.05%, compared to CANO's ROE of -1.49%. Regarding short-term risk, ASTH is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check CANO's competition here
Avem Health Partners, Inc. (NYSE: FPCG)
ASTH vs FPCG Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas FPCG's P/E ratio is 0.09. In terms of profitability, ASTH's ROE is +0.05%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, ASTH is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check FPCG's competition here
American Shared Hospital Services (AMEX: AMS)
ASTH vs AMS Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AMS has a market cap of 9.9M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AMS trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AMS's P/E ratio is -6.69. In terms of profitability, ASTH's ROE is +0.05%, compared to AMS's ROE of -0.07%. Regarding short-term risk, ASTH is more volatile compared to AMS. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check AMS's competition here
Field Trip Health Ltd. (NASDAQ: FTRP)
ASTH vs FTRP Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas FTRP's P/E ratio is -1.22. In terms of profitability, ASTH's ROE is +0.05%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, ASTH is less volatile compared to FTRP. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check FTRP's competition here
Basel Medical Group Ltd Ordinary Shares (NASDAQ: BMGL)
ASTH vs BMGL Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, BMGL has a market cap of 7.7M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while BMGL trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas BMGL's P/E ratio is -0.93. In terms of profitability, ASTH's ROE is +0.05%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, ASTH is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check BMGL's competition here
XWELL, Inc. (NASDAQ: XWEL)
ASTH vs XWEL Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, XWEL has a market cap of 7.5M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while XWEL trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas XWEL's P/E ratio is -0.18. In terms of profitability, ASTH's ROE is +0.05%, compared to XWEL's ROE of +3.18%. Regarding short-term risk, ASTH is less volatile compared to XWEL. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check XWEL's competition here
20/20 Biolabs Inc. (NASDAQ: AIDX)
ASTH vs AIDX Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AIDX has a market cap of 6.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AIDX trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AIDX's P/E ratio is -0.96. In terms of profitability, ASTH's ROE is +0.05%, compared to AIDX's ROE of +2.14%. Regarding short-term risk, ASTH is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AIDX's competition here
ModivCare Inc. (NASDAQ: MODV)
ASTH vs MODV Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas MODV's P/E ratio is -0.06. In terms of profitability, ASTH's ROE is +0.05%, compared to MODV's ROE of +1.36%. Regarding short-term risk, ASTH is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check MODV's competition here
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst (NASDAQ: STLNW)
ASTH vs STLNW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, STLNW has a market cap of 5.8M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while STLNW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas STLNW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to STLNW's ROE of N/A. Regarding short-term risk, ASTH is less volatile compared to STLNW. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check STLNW's competition here
Greenbrook TMS Inc. (NASDAQ: GBNH)
ASTH vs GBNH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas GBNH's P/E ratio is -0.06. In terms of profitability, ASTH's ROE is +0.05%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, ASTH is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check GBNH's competition here
Regional Health Properties, Inc. (AMEX: RHE-PA)
ASTH vs RHE-PA Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, ASTH's ROE is +0.05%, compared to RHE-PA's ROE of +1.09%. Regarding short-term risk, ASTH is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check RHE-PA's competition here
Regional Health Properties, Inc. (AMEX: RHE)
ASTH vs RHE Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas RHE's P/E ratio is -1.79. In terms of profitability, ASTH's ROE is +0.05%, compared to RHE's ROE of -1.31%. Regarding short-term risk, ASTH is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check RHE's competition here
The Oncology Institute, Inc. (NASDAQ: TOIIW)
ASTH vs TOIIW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, TOIIW has a market cap of 4.7M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas TOIIW's P/E ratio is -0.17. In terms of profitability, ASTH's ROE is +0.05%, compared to TOIIW's ROE of +2.10%. Regarding short-term risk, ASTH is more volatile compared to TOIIW. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check TOIIW's competition here
IMAC Holdings, Inc. (NASDAQ: IMACW)
ASTH vs IMACW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas IMACW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, ASTH is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check IMACW's competition here
Nakamoto Inc. (NASDAQ: NAKAW)
ASTH vs NAKAW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, NAKAW has a market cap of 1.5M. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while NAKAW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas NAKAW's P/E ratio is -0.53. In terms of profitability, ASTH's ROE is +0.05%, compared to NAKAW's ROE of -1.05%. Regarding short-term risk, ASTH is more volatile compared to NAKAW. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check NAKAW's competition here
Concord Medical Services Holdings Limited (NYSE: CCM)
ASTH vs CCM Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, CCM has a market cap of 706.2K. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while CCM trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas CCM's P/E ratio is -0.32. In terms of profitability, ASTH's ROE is +0.05%, compared to CCM's ROE of +0.06%. Regarding short-term risk, ASTH is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check CCM's competition here
NewGenIvf Group Limited (NASDAQ: NIVF)
ASTH vs NIVF Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, NIVF has a market cap of 104.1K. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while NIVF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas NIVF's P/E ratio is 0.27. In terms of profitability, ASTH's ROE is +0.05%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, ASTH is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check NIVF's competition here
Mobile-health Network Solutions Class A Ordinary Shares (NASDAQ: MNDR)
ASTH vs MNDR Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, MNDR has a market cap of 40.8K. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while MNDR trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas MNDR's P/E ratio is -0.04. In terms of profitability, ASTH's ROE is +0.05%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, ASTH is less volatile compared to MNDR. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check MNDR's competition here
NewGenIvf Group Limited (NASDAQ: NIVFW)
ASTH vs NIVFW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, NIVFW has a market cap of 39.8K. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, ASTH's ROE is +0.05%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, ASTH is more volatile compared to NIVFW. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check NIVFW's competition here
Talkspace, Inc. (NASDAQ: TALKW)
ASTH vs TALKW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, TALKW has a market cap of 33.5K. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas TALKW's P/E ratio is 0.00. In terms of profitability, ASTH's ROE is +0.05%, compared to TALKW's ROE of +0.00%. Regarding short-term risk, ASTH is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check TALKW's competition here
Kindred Healthcare, Inc. (NYSE: KND)
ASTH vs KND Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, KND has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas KND's P/E ratio is -1.14. In terms of profitability, ASTH's ROE is +0.05%, compared to KND's ROE of -0.53%. Regarding short-term risk, ASTH is more volatile compared to KND. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check KND's competition here
New Frontier Health Corporation (NYSE: NFH)
ASTH vs NFH Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, NFH has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas NFH's P/E ratio is -19.75. In terms of profitability, ASTH's ROE is +0.05%, compared to NFH's ROE of -0.06%. Regarding short-term risk, ASTH is more volatile compared to NFH. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check NFH's competition here
ATI Physical Therapy, Inc. (NYSE: ATIP-WT)
ASTH vs ATIP-WT Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, ASTH is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check ATIP-WT's competition here
Diversicare Healthcare Services, Inc. (NASDAQ: DVCR)
ASTH vs DVCR Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas DVCR's P/E ratio is 28.34. In terms of profitability, ASTH's ROE is +0.05%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, ASTH is more volatile compared to DVCR. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check DVCR's competition here
Skylight Health Group Inc. (NASDAQ: SLHG)
ASTH vs SLHG Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas SLHG's P/E ratio is -1.48. In terms of profitability, ASTH's ROE is +0.05%, compared to SLHG's ROE of N/A. Regarding short-term risk, ASTH is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check SLHG's competition here
Hanger, Inc. (NYSE: HNGR)
ASTH vs HNGR Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas HNGR's P/E ratio is 19.71. In terms of profitability, ASTH's ROE is +0.05%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, ASTH is more volatile compared to HNGR. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check HNGR's competition here
Almost Family Inc. (NASDAQ: AFAM)
ASTH vs AFAM Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas AFAM's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, ASTH is less volatile compared to AFAM. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check AFAM's competition here
Skylight Health Group Inc. (NASDAQ: SLHGP)
ASTH vs SLHGP Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, ASTH's ROE is +0.05%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, ASTH is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check SLHGP's competition here
SOC Telemed, Inc. (NASDAQ: TLMD)
ASTH vs TLMD Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas TLMD's P/E ratio is -1.60. In terms of profitability, ASTH's ROE is +0.05%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, ASTH is more volatile compared to TLMD. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check TLMD's competition here
SOC Telemed, Inc. (NASDAQ: TLMDW)
ASTH vs TLMDW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas TLMDW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, ASTH is less volatile compared to TLMDW. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check TLMDW's competition here
Tivity Health, Inc. (NASDAQ: TVTY)
ASTH vs TVTY Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas TVTY's P/E ratio is 19.06. In terms of profitability, ASTH's ROE is +0.05%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, ASTH is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for ASTH.Check TVTY's competition here
DocGo Inc. (NASDAQ: DCGOW)
ASTH vs DCGOW Comparison August 2026
Astrana Health, Inc. (NASDAQ: ASTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 2B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, ASTH is priced at $39.19 on the NASDAQ, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 37.88, whereas DCGOW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.05%, compared to DCGOW's ROE of -0.00%. Regarding short-term risk, ASTH is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for ASTH.Check DCGOW's competition here